Daiwa Securities Group
DAWN

Daiwa Securities Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Daiwa Securities Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-296
Closed -$3K – 1251
2025
Q4 		$3K Hold
296
– – ﹤0.01% 1271
2025
Q3 		$2K Hold
296
– – ﹤0.01% 1263
2025
Q2 		$2K Hold
296
– – ﹤0.01% 1211
2025
Q1 		$2K Hold
296
– – ﹤0.01% 1181
2024
Q4 		$4K Hold
296
– – ﹤0.01% 1172
2024
Q3 		$4K Hold
296
– – ﹤0.01% 1180
2024
Q2 		$4K Hold
296
– – ﹤0.01% 1210
2024
Q1 		$5K Hold
296
– – ﹤0.01% 1205
2023
Q4 		$4K Hold
296
– – ﹤0.01% 1222
2023
Q3 		$4K Hold
296
– – ﹤0.01% 1171
2023
Q2 		$4K Hold
296
– – ﹤0.01% 1194
2023
Q1 		$4K Hold
296
– – ﹤0.01% 1163
2022
Q4 		$6K Buy
296
+115
+64% +$2.36K ﹤0.01% 1139
2022
Q3 		$4K Hold
181
– – ﹤0.01% 1173
2022
Q2 		$3K Hold
181
– – ﹤0.01% 1197
2022
Q1 		$2K Hold
181
– – ﹤0.01% 1246
2021
Q4 		$3K Buy
+181
New +$3.72K ﹤0.01% 1238

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Daiwa Securities Group's DAWN Position: Q1 2026 in Review

Daiwa Securities Group sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 296 shares — an estimated $3K sold.

Daiwa Securities Group first reported a position in DAWN in Q4 2021 and held it in 17 quarters. The position peaked at $6K in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Daiwa Securities Group reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 296 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3K.
  • Daiwa Securities Group first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Day One Biopharmaceuticals position peaked at $6K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.